Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6672119 | 0.98 | AKR1C1 (0.68) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL65167 | 0.83 | AKR1C1 (1.00) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL3107522 | 0.83 | AKR1C1 (0.76) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL9577294 | 0.82 | AKR1C1 (0.48) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL9577271 | 0.82 | HDAC4 (0.62) | AKR1C1HDAC4HSD11B1ALDH1A1HDAC1 | |
| SCHEMBL19249602 | 0.81 | AKR1C1 (0.96) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| Hydrochloric Acid SCHEMBL8315894 | 0.81 | AKR1C1 (0.96) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL66387 | 0.81 | AKR1C1 (0.96) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL1041902 | 0.81 | AKR1C1 (0.96) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL2440267 | 0.81 | AKR1C1 (0.73) | AKR1C1HDAC4MEN1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-0407588-B1 | PROCESS FOR PRODUCING 2-OXO-3-AROMATIC CARBOXYLIC ACID DERIVATIVES | SAGAMI CHEM RES (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5028738-A | Process for producing 2-oxo-3-aromatic carboxylic acid derivatives | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0407588-A1 | PROCESS FOR PRODUCING 2-OXO-3-AROMATIC CARBOXYLIC ACID DERIVATIVES | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | AKR1C1 485/4885HDAC4 648/4885MEN1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.